

There are no other devices present or emerging like OFAM.

Ease of use, speed and high sensitivity that correlates with clinical outcomes Has the ability to track/moderate therapies

NEED FOR OFAM

- Currently there is only one other commercial device. This instrument is too expensive and does not have the accuracy to measure flare in a clinical setting to be useful
- Price and accuracy are major drivers. A portable low cost device that can be used in a large variety of patients (children to adults) is highly desirable

CHROMOLOGIC ADVANTAGE

ChromoLogic has commercialized ocular diagnostic offerings, with sales to Fortune 500 organizations.

MARKET OPPORTUNITY

- As the OFAM technology is for ocular inflammation quantification, it will be part of the global ophthalmic diagnostic equipment market, valued at around \$2.6 billion.
- By providing disruptive sensitivity and specificity in unambiguously diagnosing ocular flare in a handheld platform,
 OFAM is expected to find widespread clinical use in order to address the compelling need for preventing visual handicaps





\$2.6Billion

value of global opthalmic diagnostic market

~\$200m

estimated global market value

5-30

second operation time with no light change